Impact of Cytopenias in Patients Treated with Ruxolitinib Versus Best Available Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease: A REACH2 Post Hoc Analysis

Category Primary study
JournalTransplantation and cellular therapy
Year 2023
This article has no abstract
Epistemonikos ID: 90ee13aa365d15f03ce221d1b47408f658770e18
First added on: Feb 16, 2024